Yahav Achim Ve Achayot - Provident Funds Management Company’s UroGen Pharma URGN Stock Holding History

Yahav Achim Ve Achayot - Provident Funds Management Company’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-25,330	Closed	-$212K	–	66
2022 Q4	$212K	Hold	25,330	–	–	0.2%	56
2022 Q3	$208K	Hold	25,330	–	–	0.2%	54
2022 Q2	$206K	Hold	25,330	–	–	0.18%	56
2022 Q1	$219K	Hold	25,330	–	–	0.17%	55
2021 Q4	$251K	Hold	25,330	–	–	0.18%	53
2021 Q3	$426K	Buy	+25,330	New	+$401K	0.33%	50

Other funds holding URGN

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Yahav Achim Ve Achayot - Provident Funds Management Company's URGN Position: Q1 2023 in Review

Yahav Achim Ve Achayot - Provident Funds Management Company sold out of UroGen Pharma (URGN) in Q1 2023, closing a stake of 25,330 shares — an estimated $212K sold.

Yahav Achim Ve Achayot - Provident Funds Management Company first reported a position in URGN in Q3 2021 and held it in 6 quarters. The position peaked at $426K in Q3 2021. 65 funds tracked by Wall St. Rank hold URGN as of Q1 2023.

Yahav Achim Ve Achayot - Provident Funds Management Company reported no remaining UroGen Pharma position as of Q1 2023 after selling out during the quarter.
Yahav Achim Ve Achayot - Provident Funds Management Company sold 25,330 UroGen Pharma shares in Q1 2023, an estimated $212K.
Yahav Achim Ve Achayot - Provident Funds Management Company first reported a position in UroGen Pharma in Q3 2021 and held it in 6 quarters.
Yahav Achim Ve Achayot - Provident Funds Management Company's UroGen Pharma position peaked at $426K in Q3 2021.
65 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2023.

Based on Yahav Achim Ve Achayot - Provident Funds Management Company's 13F filing for Q1 2023, filed 11 May 2023.